Vertex Pharmaceuticals Inc (VRTX)

NASDAQ
Currency in USD
Disclaimer
319.98
-1.47
(-0.46%)
Closed
319.90
-0.08
(-0.03%)
Pre Market
Real-time Data
Day's Range
319.23
322.69
52 wk Range
225.28
324.75
Volume
2,204,154
Prev. Close
321.45
Open
321.21
Day's Range
319.23-322.69
52 wk Range
225.28-324.75
Volume
2,204,154
Average Volume (3m)
1,411,970
1-Year Change
31.67%
Shares Outstanding
256,691,452
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
329.20
Upside +2.88%

Vertex Pharmaceuticals Inc News

Vertex Pharmaceuticals Inc Analysis

Vertex Pharmaceuticals Inc Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF) and it has several ongoing clinical and research programs to advance and extend treatment of CF. The Company's marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Its four medicines are being used to treat the people with CF in North America, Europe and Australia. The Company has a pipeline of investigational therapies in other serious diseases where it is leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. The Company’s other pipeline products include CTX001, VX-147, VX-121, VX-561, VX-548, and VX-880.